Pacira BioSciences (NASDAQ:PCRX – Get Free Report) and Skye Bioscience (NASDAQ:SKYE – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings.
Profitability
This table compares Pacira BioSciences and Skye Bioscience’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pacira BioSciences | -13.07% | 13.42% | 7.19% |
| Skye Bioscience | N/A | -45.78% | -37.44% |
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Pacira BioSciences and Skye Bioscience, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pacira BioSciences | 2 | 4 | 4 | 0 | 2.20 |
| Skye Bioscience | 0 | 0 | 6 | 0 | 3.00 |
Institutional and Insider Ownership
99.7% of Pacira BioSciences shares are held by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are held by institutional investors. 6.4% of Pacira BioSciences shares are held by company insiders. Comparatively, 3.0% of Skye Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Pacira BioSciences and Skye Bioscience”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pacira BioSciences | $674.98 million | 1.14 | $41.96 million | ($2.03) | -8.18 |
| Skye Bioscience | N/A | N/A | -$37.65 million | N/A | N/A |
Pacira BioSciences has higher revenue and earnings than Skye Bioscience.
Risk and Volatility
Pacira BioSciences has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Skye Bioscience has a beta of 1.74, suggesting that its share price is 74% more volatile than the S&P 500.
Summary
Pacira BioSciences beats Skye Bioscience on 6 of the 11 factors compared between the two stocks.
About Pacira BioSciences
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
About Skye Bioscience
Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
